![]() |
|
|
Department of Pharmacology and Therapeutics, University of
Liverpool
The urinary metabolites of carbamazepine (CBZ) in epileptic
patients receiving long-term drug treatment have been characterized by
LC/MS. CBZ-10,11-epoxide (9.6-15.0 µg/ml),
trans-10,11-dihydrodiol-CBZ (273.0-400.00 µg/ml), and
CBZ (2.4-3.8 µg/ml) were measured by HPLC. The secondary
N-glucuronide of CBZ, four phenolic
O-glucuronides (including those of 2- and 3-OH-CBZ), two
additional OH-CBZ O-glucuronides, and the
N-glucuronide of CBZ-10,11-epoxide constituted the products of either direct conjugation or preliminary monoxygenation. Derivatives of these monoxygenated compounds, which were characterized as O-glucuronides, were represented by dihydroxylated
(catechol) CBZ and its putative O-methyl metabolite and by
10,11-dihydrodiol-CBZ. 10,11-Dihydro-10-OH-CBZ
O-glucuronide, a metabolite thought to be excreted only by
uremic subjects, was not found. More complicated biotransformations of
the 10,11-ene moiety were revealed by two carbinol products of azepine
ring contraction: 9-OH-methyl-10-carbamoyl acridan and an hydroxylated
derivative thereof, which were excreted as O-glucuronides.
No polar sulfur-containing metabolites that might serve as indicators
of reactive intermediate formation were found in human urine.
This article has been cited by other articles:
![]() |
A. G. Staines, M. W. H. Coughtrie, and B. Burchell N-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7 J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1131 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Naisbitt, M. Britschgi, G. Wong, J. Farrell, J. P. H. Depta, D. W. Chadwick, W. J. Pichler, M. Pirmohamed, and B. K. Park Hypersensitivity Reactions to Carbamazepine: Characterization of the Specificity, Phenotype, and Cytokine Profile of Drug-Specific T Cell Clones Mol. Pharmacol., March 1, 2003; 63(3): 732 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ju and J. P. Uetrecht Detection of 2-Hydroxyiminostilbene in the Urine of Patients Taking Carbamazepine and Its Oxidation to a Reactive Iminoquinone Intermediate J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 51 - 56. [Abstract] [Full Text] |
||||